Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
Merus (NASDAQ: MRUS) had its "outperform" rating re-affirmed by analysts at William Blair.
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.